|
|
|
|
| LEADER |
00000cam a2200000Ia 4500 |
| 001 |
SCIDIR_on1337404611 |
| 003 |
OCoLC |
| 005 |
20231120010656.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
220728s2022 enk o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d OPELS
|d SFB
|d OCLCF
|d OCLCQ
|d N$T
|d OCLCO
|
| 020 |
|
|
|a 9780323919531
|q (electronic bk.)
|
| 020 |
|
|
|a 0323919537
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323918657
|
| 020 |
|
|
|z 0323918654
|
| 035 |
|
|
|a (OCoLC)1337404611
|
| 050 |
|
4 |
|a RS199.5
|
| 082 |
0 |
4 |
|a 615.6
|2 23
|
| 245 |
0 |
0 |
|a Applications of nanovesicular drug delivery
|h [electronic resource] /
|c edited by Amit Kumar Nayak [and more].
|
| 260 |
|
|
|a London :
|b Academic Press,
|c 2022.
|
| 300 |
|
|
|a 1 online resource
|
| 505 |
0 |
|
|a Front Cover -- Applications of Nanovesicular Drug Delivery -- Copyright Page -- Contents -- List of contributors -- Preface -- 1 Targeting cellular and molecular mechanisms of nanovesicular systems for the treatment of different diseases -- 1.1 Introduction -- 1.2 Lipid nanovesicular systems -- 1.2.1 Liposomes -- 1.2.2 Elastic liposomes: ethosomes and transferosomes -- 1.2.3 Niosomes -- 1.2.4 Ufasomes -- 1.3 Polymer nanovesicular systems -- 1.3.1 Polymersomes/polymer vesicles -- 1.3.2 Nanovesicular systems for targeting to cellular mechanisms -- 1.3.3 Nanovesicular systems for targeting molecular mechanisms and the era of CRISPR/CAS9 -- 1.3.4 Nanovesicular systems for the treatment of different diseases -- 1.4 Conclusions -- References -- 2 Nanovesicles for drug codelivery -- 2.1 Introduction -- 2.2 Combination drug therapy -- 2.3 General overview of nanovesicles -- 2.3.1 Liposomes -- 2.3.2 Niosomes -- 2.3.3 Exosomes -- 2.3.4 Spanlastics -- 2.4 Design and preparation techniques of codelivery nanovesicles -- 2.4.1 Mechanical dispersion/film hydration method -- 2.4.2 Ultrasonication method -- 2.4.3 Self-assembling -- 2.4.4 Solvent dispersion methods -- 2.4.5 Detergent removal method -- 2.4.6 Microfluidization method -- 2.4.7 Handjani-Vila method -- 2.5 Nanodrug codelivery systems -- 2.5.1 Nanovesicles-hydrogels for codelivery of drugs -- 2.5.2 Nanovesicles for codelivery of anticancer drugs -- 2.5.3 Nanovesicles for codelivery of cardiovascular drugs -- 2.5.4 Nanovesicles for codelivery of antibacterial/antiinflammatory drugs -- 2.6 Conclusion -- References -- 3 Theranostic nanovesicles -- 3.1 Introduction -- 3.2 Imaging strategies -- 3.2.1 Optical imaging -- 3.2.2 Magnetic resonance imaging -- 3.2.3 Radionuclide-based imaging -- 3.2.4 Computed tomography -- 3.2.5 Ultrasound -- 3.3 Different nanovesicles used as theranostic system.
|
| 505 |
8 |
|
|a 3.3.1 Liposomes -- 3.3.2 Ethosomes -- 3.3.3 Transferosomes -- 3.3.4 Niosomes -- 3.3.5 Polymersomes -- 3.4 Conclusion -- References -- 4 Nanovesicles for ocular drug delivery -- 4.1 Introduction -- 4.2 Physiology, routes of drug administration and ocular barriers for drug penetration -- 4.2.1 Physiology of the eye -- 4.2.2 Routes of drug administration to the eye and corresponding ocular barriers -- 4.3 Ocular diseases -- 4.3.1 Anterior segment diseases -- 4.3.2 Posterior segment diseases -- 4.4 Nanovesicles for ocular drug delivery -- 4.4.1 Preclinical studies -- 4.4.1.1 Nanovesicles for anterior segment disease treatment -- 4.4.1.2 Nanovesicles for posterior segment disease treatment -- 4.4.1.3 Nanovesicle assisted gene therapy for ocular disease treatment -- 4.4.2 Clinical studies and approved products -- 4.5 Conclusions and future perspectives -- Acknowledgments and funding -- References -- 5 Nanovesicles for nasal drug delivery -- 5.1 Introduction -- 5.2 Intranasal drug delivery system -- 5.3 Dosage forms and absorption enhancers -- 5.3.1 Nasal drops -- 5.3.2 Nasal spray -- 5.3.3 Nasal gel -- 5.3.4 Nasal powders -- 5.4 Benefits of intranasal drug delivery -- 5.5 Barriers in nasal distribution -- 5.5.1 Poor bioavailability -- 5.5.2 Biliary clearance -- 5.5.3 Enzyme degradation -- 5.6 Need for intranasal drug delivery system -- 5.7 Anatomy and physiology of nasal route -- 5.8 Mechanism of absorption of drugs via nasal route -- 5.8.1 Intracellular pathway -- 5.8.2 Transcellular transport -- 5.9 Nasal devices -- 5.10 Role of nanotechnology intranasal drug delivery -- 5.11 Nanovesicles for intranasal drug delivery -- 5.11.1 Lipid based nanovesicles -- 5.11.1.1 Liposomes -- 5.11.1.1.1 Method of preparation of liposomes -- 5.11.1.2 Transfersomes -- 5.11.1.2.1 Method of preparation of transfersomes -- 5.11.1.3 Ethosomes.
|
| 505 |
8 |
|
|a 5.11.1.3.1 Method of preparation of ethosomes -- 5.11.1.4 Magnesomes -- 5.11.1.4.1 Method of preparation of magnesomes -- 5.11.1.5 Ufasome -- 5.11.1.5.1 Method of preparation of ufasomes -- 5.11.1.6 Novasomes -- 5.11.1.6.1 Method of preparation of novasomes -- 5.11.2 Nonionic surfactant based nanovesicles -- 5.11.2.1 Niosomes -- 5.11.2.1.1 Method of preparation of niosomes -- 5.11.2.2 Spanlastics -- 5.11.2.2.1 Method of Preparation of spanlastics -- 5.11.3 Biologically derived nanovesicles -- 5.11.3.1 Exosomes -- 5.11.3.1.1 Method of preparation of exosomes -- 5.12 Applications of nanovesicular intranasal delivery system -- 5.12.1 Viral infection -- 5.12.2 Osteoclastic bone resorption -- 5.12.3 Central nervous system disorders -- 5.12.4 Migraine -- 5.12.5 Hypertension -- 5.12.6 Anxiety disorders -- 5.12.7 Antinociceptive -- 5.12.8 Oxytocin and insulin delivery -- 5.12.9 Cancer -- 5.12.10 Neurodegenerative/brain inflammatory disease -- 5.12.11 Cerebral arteriosclerosis, thrombosis, and vertigo disorders -- 5.13 Conclusion -- References -- 6 Nanovesicles for transdermal drug delivery -- 6.1 Introduction -- 6.1.1 The mechanisms of interactions between nanovesicle systems and skin -- 6.2 Lipid-based vesicular nanostructures for transdermal drug delivery -- 6.2.1 Traditional liposomes as skin drug delivery systems -- 6.2.2 Transfersomes -- 6.2.3 Ethosomes -- 6.2.4 Invasome -- 6.2.5 Glycerosomes -- 6.2.6 Hyalurosomes -- 6.3 Nanovesicles formed by nonlipid building blocks -- 6.3.1 Niosomes as transdermal drug delivery systems -- 6.3.2 Polymersomes as transdermal drug delivery systems -- 6.4 Conclusion and future perspective -- References -- 7 Nanovesicles for intravenous drug delivery -- 7.1 Introduction -- 7.2 Intravenous drug administration -- 7.3 Nanovesicular systems -- 7.3.1 Liposomes -- 7.3.2 Niosomes -- 7.3.3 Polymersomes -- 7.3.4 Transfersomes.
|
| 505 |
8 |
|
|a 7.3.5 Ethosomes and ethosomal nanovesicles -- 7.3.6 Phytosomes -- 7.3.7 Extracellular vesicles -- 7.4 Intravenous nanovesicles for imaging -- 7.5 Intraveneous nanovesicles for therapy -- 7.5.1 Tumor targeting and cancer therapy -- 7.5.2 Fungal infections -- 7.5.3 Pain management and inflammatory diseases -- 7.5.4 Others -- 7.6 Intravenous nanovesicles for gene therapy -- 7.6.1 Intravenous nanovesicular systems developed for gene augmentation -- 7.6.2 Intravenous nanovesicular systems developed for gene silencing (suppression) -- 7.6.3 Intravenous nanovesicular systems developed for genome editing -- 7.7 Intravenous nanovesicles for theranostic -- 7.8 Conclusion -- References -- 8 Nanovesicles for target specific drug delivery -- 8.1 Introduction -- 8.2 Liposomes as drug delivery vesicles -- 8.2.1 Types of liposomes -- 8.2.2 Applications -- 8.3 Polymeric micelles as drug delivery vehicles -- 8.3.1 Applications -- 8.4 Exosomes as drug delivery vesicles -- 8.4.1 Applications -- 8.5 Niosomes-drug delivery vesicles -- 8.5.1 Applications -- 8.6 New era of vesicular drug delivery systems -- 8.6.1 Transferosomes -- 8.6.2 Ethosomes -- 8.6.3 Sphingosomes -- 8.6.4 Cubosomes -- 8.6.5 Ufasomes -- 8.6.6 Colloidosomes -- 8.6.7 Aquasomes -- 8.6.8 Polymerosomes -- 8.6.9 Emulsomes -- 8.6.10 Virosomes -- 8.6.11 Enzymosomes -- 8.6.12 Pharmacosomes -- 8.7 Conclusions -- References -- 9 Blood-brain barrier and nanovesicles for brain-targeting drug delivery -- 9.1 Introduction -- 9.2 Neurovascular unit -- 9.2.1 Blood-brain barrier and blood-cerebrospinal fluid barrier roles -- 9.2.2 Immunosurveillance in neurovascular unit -- 9.2.3 Tight junctional molecular machinery -- 9.2.4 Blood-brain barrier models -- 9.2.5 Blood-brain barrier transport machinery -- 9.2.6 Endocytosis, transcytosis, and vesicular trafficking -- 9.2.7 Nanovesicles delivery mechanisms.
|
| 650 |
|
0 |
|a Drug delivery systems.
|
| 650 |
|
0 |
|a Nanomedicine.
|
| 650 |
|
2 |
|a Drug Delivery Systems
|0 (DNLM)D016503
|
| 650 |
|
2 |
|a Nanomedicine
|0 (DNLM)D050997
|
| 650 |
|
6 |
|a Syst�emes d'administration de m�edicaments.
|0 (CaQQLa)000260397
|
| 650 |
|
6 |
|a Nanom�edecine.
|0 (CaQQLa)201-0448752
|
| 650 |
|
7 |
|a Drug delivery systems
|2 fast
|0 (OCoLC)fst00898667
|
| 650 |
|
7 |
|a Nanomedicine
|2 fast
|0 (OCoLC)fst01744350
|
| 700 |
1 |
|
|a Nayak, Amit Kumar.
|
| 776 |
0 |
8 |
|i Print version:
|z 9780323919531
|
| 776 |
0 |
8 |
|i Print version:
|z 0323918654
|z 9780323918657
|w (OCoLC)1284290617
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780323918657
|z Texto completo
|
